Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter pharmacokinetic study of mirikizumab in pediatric patients with moderately to severely active ulcerative colitis
MOH_2020-06-15_008793Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mirikizumab in autoimmune colitis (3 arms), sponsored by Eli Lilly and Company. Started Jun 2020; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2020-06-15_008793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-15_008793.